[Management of Parkinson's syndrome using levadopa. Results of a long-term study].
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003863:Depression / Q000139:chemically induced; D004295:Dihydroxyphenylalanine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005149:Facial Expression; D005260:Female; D006801:Humans; D006948:Hyperkinesis / Q000139:chemically induced; D007022:Hypotension / Q000139:chemically induced; D007806:Language Disorders / Q000188:drug therapy; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D011187:Posture / Q000187:drug effects; D014202:Tremor / Q000188:drug therapy
D000978:Antiparkinson Agents; D004295:Dihydroxyphenylalanine
Die Behandlung des Parkinson-Syndroms mit Levodopa. Ergebnisse einer Langzeitstudie.